Melvin D. Booth
Chairman
Melvin D. Booth joined the board of directors of Prestwick Pharmaceuticals, Inc., in 2004, and currently serves as Chairman. Before joining Prestwick Pharmaceuticals, Mr. Booth was most recently President and Chief Operating Officer and Director of MedImmune, Inc. He retired in January, 2004 as President & Chief Operating Officer and from the Board in March, 2005. Prior to joining MedImmune, Mr. Booth served as President and Chief Operating Officer of Human Genome Sciences, Inc. (July 1995 to October 1998). He was also a member of the company's executive committee and board of directors.
Before joining Human Genome Sciences, Mr. Booth served for a number of years with Syntex Corporation, where he held a variety of positions within the company and its subsidiaries from 1975 to 1995. He was President of Syntex Laboratories, Inc., from 1993 to 1995, and served as Vice President of Syntex Corporation from 1992 to 1995. From 1992 to 1993, he served as President of Syntex Pharmaceuticals Pacific and from 1991 to 1992 he served as Vice President of Syntex, Inc. Prior to that time, Mr. Booth served as President of Syntex, Inc., Canada, from 1986 to 1991. Mr. Booth has been active in the U.S. pharmaceutical industry organizations and is also a past chairman of the Pharmaceutical Manufacturers Association of Canada. In addition to his role at Prestwick Pharmaceuticals, he currently serves on the boards of Focus Technologies, Inc., Millipore Corporation, PRA International, Inc., and Ventria BioSciences, Inc. Mr. Booth graduated with honors and holds an honorary Doctor of Science degree from Northwest Missouri State University. He is a certified public accountant.
George F. Horner III
President and Chief Executive Officer
Mr. Horner joined Prestwick in August 2006 and is our President and Chief Executive Officer. Most recently he worked at Vicuron Pharmaceuticals, Inc. where he served as president, chief executive officer and a director from 1996 until the company was acquired by Pfizer, Inc. in September 2005. Prior to Vicuron, Mr. Horner worked as a corporate vice president at Ligand Pharmaceuticals from 1993 to 1995, and before that, he spent nearly two decades in a variety of executive positions at Abbott Laboratories. He is a member of the board of directors of Endo Pharmaceuticals, Inc.
Patrick Enright
Managing Director
Longitude Capital
Patrick Enright is a founder and Managing Director of Longitude Capital. He focuses on investments in biotechnology. From 2002 through 2006, Mr. Enright was a Managing Director of Pequot Ventures where he co-led the life sciences investment practice. Prior to Pequot, he was a Managing Member responsible for the Delta Opportunity Fund, where he invested in privately-held and publicly-traded biotechnology companies, such as SUGEN, Inc. and Cephalon, Inc. Mr. Enright began his investment career at PaineWebber Development Corporation, a direct investment group focused primarily on biotechnology companies. Mr. Enright also has significant life sciences operations experience. He was CFO and Senior Vice President Business Development of Valentis, Inc. (NASDAQ: VLTS) and Senior Vice President Finance and Business Development of Boehringer Mannheim Pharmaceuticals (now Hoffmann-La Roche). Mr. Enright began his life sciences career 23 years ago at Sandoz (now Novartis). He currently serves on the boards of Threshold Pharmaceuticals (NASDAQ: THLD), Sequenom (NASDAQ: SQNM), DiObex, Codexis, Horizon Therapeutics, MAP Pharmaceuticals, Prestwick Pharmaceuticals, Raven biotechnologies and InfaCare Pharmaceuticals. Mr. Enright holds an M.B.A. from the Wharton School of Business at the University of Pennsylvania and a B.S. in Biological Sciences from Stanford University.
Stewart Hen
Managing Director
Warburg Pincus, LLC
Mr. Hen is a Managing Director at Warburg Pincus LLC based in New York. He focuses on life sciences investments including biotechnology, pharmaceuticals, specialty pharmaceuticals, and drug delivery. Mr. Hen has over fifteen years experience in the biotechnology and pharmaceutical industries. Prior to joining Warburg Pincus, Mr. Hen was a consultant at McKinsey & Company where he advised life sciences companies on a range of strategic issues. Prior to McKinsey, he worked at Merck in both R&D and manufacturing. Mr. Hen holds a M.B.A. from The Wharton School where he was named a Palmer Scholar, a M.S. in chemical engineering from the Massachusetts Institute of Technology where he was a National Science Foundation Fellow, and a B.S. in chemical engineering from the University of Delaware. Mr. Hen is a director of Allos Pharmaceuticals, Altus Pharmaceuticals, Neurogen Corporation and RibX Pharmaceuticals, and formerly of The Medicines Company, Triangle Pharmaceuticals and Synaptic Pharmaceuticals. He also serves on the Health Care & Sciences Group of the New York City Investment Fund.
Arthur M. Mandell
Director
Prestwick Pharmaceuticals, Inc.
Mr. Mandell has served as a Director of the Company since October 2005. Mr. Mandell brings over 25 years of healthcare management experience in both the pharmaceutical and biotechnology sectors, with extensive expertise in business development, strategic planning, product development, and commercialization of products and services. Most recently, Mr. Mandell was President, Chief Executive Officer, and a director of Cellective Therapeutics, Inc., a Maryland-based mononclonal antibody company which was acquired by MedImmune Inc. in October, 2005. Prior to joining Cellective, Mr. Mandell was President, Chief Executive Officer, and a director of Stemron Corporation, a therapeutic stem cell start up company in Gaithersburg, Maryland. Prior to joining Stemron Corporation, Mr. Mandell served as Senior Vice President and Chief Business Officer of Human Genome Sciences, Inc. (HGS), in Gaithersburg, Maryland. He was instrumental in aiding HGS' transition from a drug discovery company to a biopharmaceutical company. Mr. Mandell began his career in California, where he spent over 13 years in various leadership positions, both domestic and international, at Syntex Corporation. He also has experience in the pharmaceutical/biotechnology service sector in his capacity as General Partner and West Coast General Manager for ZS Associates, a healthcare consulting firm.
Ernest Mario, PhD
Chairman, Pharmaceutical Product Development
Chairman and CEO, Capnia
Ernest Mario is chairman of Pharmaceutical Product Development, a leading provider of research services to the pharmaceutical industry, and chairman and CEO of Capnia, a developer of novel therapeutic products based on a proprietary medical gas delivery system.
After working as a drugstore pharmacist and then beginning his pharmaceutical industry career as a researcher in 1966, Dr. Mario served in management at a number of drug companies before being named in 1989 chief cxecutive of Glaxo, then the second-largest drug company in the world. During Dr. Mario’s tenure, Glaxo brought five major new products to market and saw sales and profits increase by 15% annually. Later Dr. Mario led pioneering drug delivery technology company Alza until selling it to Johnson & Johnson in 2001 in what was then one of the largest pharmaceutical industry mergers in history. Most recently he served as chairman and chief executive of Reliant Pharmaceuticals, where he led the commercialization of Omacor/Lovaza, the first and only prescription omega-3 medication clinically proven to dramatically reduce very high triglycerides.
Dr. Mario earned a BS in pharmacy at Rutgers and his MS and PhD in physical sciences at the University of Rhode Island. He holds honorary doctorates from URI and Rutgers, the latter of which in 2001 renamed its pharmacy school the Ernest Mario School of Pharmacy. In 2007 he was awarded the Remington Medal by the American Pharmacists’ Association, pharmacy’s highest honor.
In addition to his current and past service on a number of corporate boards, Dr. Mario is active in numerous educational and healthcare organizations, including Duke, where he is a former university trustee and chairman of the health system. |
|
